Beam Therapeutics Financials - Benzinga

SPY762.35−0.43%QQQ735.81−0.10%BTC/USD83,177.50−0.33%DIA510.84−0.62%GLD380.11+0.58%TLT77.92−0.89%

Beam Therapeutics Inc

BEAMNASDAQ

Trade with Public

Trade with Public

$24.17

-0.06-0.25%

Last update: Sep 29, 1:16 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Beam Therapeutics Financials

Beam Therapeutics (BEAM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from

Benzinga Newsdesk

PRO
Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.09) by 16.51 percent. This is a 26.02 percent increase over losses of $(1.23) per share from

Benzinga Newsdesk

PRO
Beam Therapeutics Q4 Adj. EPS $(0.10) Beats $(0.99) Estimate, Sales $114.109M Beat $12.567M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.99) by 89.92 percent. This is a 90.83 percent increase over losses of $(1.09) per share from

Benzinga Newsdesk

Earnings Summary: Beam Therapeutics Q4

Benzinga Insights

Earnings Scheduled For February 24, 2026

Benzinga Insights

PRO
Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.05) by 5.16 percent. This is a 5.98 percent increase over losses of $(1.17) per share from

Benzinga Newsdesk